3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
39
Neoplasms, Plasma Cell
13
Lymphoma
12
Neuroblastoma
10
Leukemia, Myeloid, Acute
10
Lymphoma, Large B-Cell, Diffuse
9
Immunoglobulin Light-chain Amyloidosis
8
Lymphoma, Non-Hodgkin
6
Myelodysplastic Syndromes
5
Lymphoma, Large-Cell, Immunoblastic
5
Lymphoma, Follicular
5
Uveal Melanoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms
3
Melanoma
3
Lymphoma, Mantle-Cell
3
Leukemia
3
Amyloidosis
3
Neoplasm Metastasis
2
Hodgkin Disease
2
Ganglioneuroblastoma
2
Venentoclax
1
Smoldering Multiple Myeloma
1
Sarcoma, Ewing
1
Sarcoma
1
Retinoblastoma
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms by Histologic Type
1
Interventions
Rituximab
2
Cytarabine
2
ponatinib
1
ibrutinib
1
ibritumomab tiuxetan
1
cirmtuzumab
1
amonafide
1
acalabrutinib
1
Vincristine
1
Prednisone
1
Melphalan
1
Imatinib Mesylate
1
Etoposide
1
Doxorubicin
1
Daunorubicin
1
Cyclophosphamide
1
Carmustine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphatic Diseases
×
Melphalan
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts